Logo image of XENE

XENON PHARMACEUTICALS INC (XENE) Stock Earnings & Estimates

USA - Nasdaq - NASDAQ:XENE - CA98420N1050 - Common Stock

41.16 USD
+0.89 (+2.21%)
Last: 11/21/2025, 8:06:08 PM
41.16 USD
0 (0%)
After Hours: 11/21/2025, 8:06:08 PM

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032
Revenue
YoY % growth
XENE revenue by date.XENE revenue by date.
32.17M
371.01%
18.44M
-42.68%
9.43M
-48.86%
2.11M
-100.00%
300.002K7.68M23.645M
207.88%
100.45M
324.83%
365.42M
263.78%
697.46M
90.87%
1.069B
53.27%
1.367B
27.88%
1.732B
26.70%
EBITDA
YoY % growth
XENE ebitda by date.XENE ebitda by date.
-30.66M
27.67%
-78.08M
-154.66%
-127.52M
-63.32%
-214.333M
-66.24%
-279.2M
-30.54%
-366.371M
-32.39%
-416.958M
-13.81%
-328.857M
21.13%
-275.753M
16.15%
-45.04M
83.67%
N/AN/AN/A
EBIT
YoY % growth
XENE ebit by date.XENE ebit by date.
-31.3M
26.90%
-78.99M
-152.36%
-129.14M
-63.49%
-218.198M
-65.75%
-280.316M
-30.48%
-367.641M
-31.63%
-411.631M
-11.97%
-411.442M
0.05%
-187.534M
54.42%
103.4M
155.14%
392.98M
280.06%
569.34M
44.88%
865.19M
51.96%
Operating Margin
XENE operating margin by date.XENE operating margin by date.
-97.30%-428.36%-1,369.46%-10,341.13%-93,437.77%-4,786.99%-1,740.88%-409.60%-51.32%14.83%36.76%41.65%49.95%
EPS
YoY % growth
XENE eps by date.XENE eps by date.
-0.81
47.40%
-1.77
-118.52%
-2.04
-15.25%
-2.91
-33.33%
-3.17
-11.03%
-4.33
-43.44%
-4.70
-8.56%
-4.63
1.46%
-3.23
30.22%
-0.34
89.38%
2.31
772.91%
4.35
88.34%
6.92
59.02%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27
EPS
Q2Q % growth
-1.21
-44.24%
-1.16
-39.47%
-1.20
-12.32%
-1.25
-8.48%
-1.30
-7.02%
-1.37
-18.07%
-1.45
-20.51%
-1.43
-14.46%
-1.42
-9.34%
Revenue
Q2Q % growth

-100.00%
N/AN/AN/AN/A
EBITDA
Q2Q % growth
-98.087M
-30.93%
-94.347M
-30.89%
-97.663M
-5.08%
-102.21M
-8.27%
N/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-101.882M
-31.50%
-100.283M
-37.87%
-103.016M
-9.32%
-108.522M
-12.65%
-113.895M
-11.79%
N/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2025
Q2Q % growth
-1.15
-41.98%
-1.180.032.13%
Q2 2025
Q2Q % growth
-1.07
-42.67%
-1.01-0.06-5.82%
Q1 2025
Q2Q % growth
-0.83
-33.87%
-0.930.1010.75%
Q4 2024
Q2Q % growth
-0.84
-31.25%
-0.880.044.31%
Q3 2024
Q2Q % growth
-0.81
-10.96%
-0.830.022.60%
Q2 2024
Q2Q % growth
-0.75
-4.17%
-0.71-0.04-5.10%
Q1 2024
Q2Q % growth
-0.62
1.59%
-0.680.068.49%
Q4 2023
Q2Q % growth
-0.64
-12.28%
-0.770.1317.35%
Q3 2023
Q2Q % growth
-0.73
-28.07%
-0.790.067.55%
Q2 2023
Q2Q % growth
-0.72
-30.91%
-0.71-0.01-1.23%
Q1 2023
Q2Q % growth
-0.63
-80.00%
-0.630.000.64%
Q4 2022
Q2Q % growth
-0.57
-18.75%
-0.600.034.45%
Q3 2022
Q2Q % growth
-0.57
-58.33%
-0.53-0.04-8.16%
Q2 2022
Q2Q % growth
-0.55
-7.84%
-0.49-0.06-11.64%
Q1 2022
Q2Q % growth
-0.35
16.67%
-0.410.0615.39%
Q4 2021
Q2Q % growth
-0.48
-41.18%
-0.38-0.10-26.96%
Q3 2021
Q2Q % growth
-0.36
-44.00%
-0.390.037.93%
Q2 2021
Q2Q % growth
-0.51 -0.49-0.02-4.44%
Q1 2021
Q2Q % growth
-0.42
-90.91%
-0.440.024.79%
Q4 2020
Q2Q % growth
-0.34
19.05%
-0.410.0716.61%
Q3 2020
Q2Q % growth
-0.25
24.24%
-0.15-0.10-61.86%
Q2 2020
Q2Q % growth
0.00
100.00%
-0.240.24100.00%
Q1 2020
Q2Q % growth
-0.22
47.62%
-0.330.1133.06%
Q4 2019
Q2Q % growth
-0.42 -0.490.0714.81%
Q3 2019
Q2Q % growth
-0.33 -0.490.1632.95%
Q2 2019
Q2Q % growth
-0.37 -0.470.1021.14%
Q1 2019
Q2Q % growth
-0.42 -0.37-0.05-14.38%
XENE Yearly EPS VS EstimatesXENE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4 -4 6
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q1 2025
Q2Q % growth
7.5M 1.129M6.371M564.30%
Q4 2024
Q2Q % growth
339.997K-339.997K-100.00%
Q4 2023
Q2Q % growth
1.93M-1.93M-100.00%
Q3 2023
Q2Q % growth

-100.00%
1.479M-1.479M-100.00%
Q2 2023
Q2Q % growth

-100.00%
408K-408K-100.00%
Q1 2023
Q2Q % growth

-100.00%
582.859K-582.859K-100.00%
Q4 2022
Q2Q % growth

-100.00%
2.329M-2.329M-100.00%
Q3 2022
Q2Q % growth
130K
-98.40%
3.079M-2.949M-95.78%
Q2 2022
Q2Q % growth
540K
-75.68%
3.626M-3.086M-85.11%
Q1 2022
Q2Q % growth
8.77M
101.15%
8.874M-104K-1.17%
Q4 2021
Q2Q % growth
3.74M
-27.38%
5.075M-1.335M-26.31%
Q3 2021
Q2Q % growth
8.12M
23.97%
10.43M-2.31M-22.15%
Q2 2021
Q2Q % growth
2.22M
-83.41%
2.375M-155K-6.53%
Q1 2021
Q2Q % growth
4.36M
-38.42%
3.026M1.334M44.08%
Q4 2020
Q2Q % growth
5.15M
54.65%
3.28M1.87M57.01%
Q3 2020
Q2Q % growth
6.55M
87.14%
10.257M-3.707M-36.14%
Q2 2020
Q2Q % growth
13.38M 7.037M6.343M90.14%
Q1 2020
Q2Q % growth
7.08M 4.59M2.49M54.25%
Q4 2019
Q2Q % growth
3.33M 5.1M-1.77M-34.71%
XENE Yearly Revenue VS EstimatesXENE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS1.83% -0.86% 0% -1.01%
RevenueN/A 100% 0% 1.59%